

AMENDMENTS TO THE CLAIMS

1. - 11. (Canceled)

12. (Currently amended) A method of treating neuralgia pain or neuropathic pain, in a mammal, comprising administering to a patient in need thereof a therapeutically effective amount of a combination of retigabine or a therapeutically utilizable salt thereof with a voltage-gated sodium channel-inhibiting substance inhibitor or a therapeutically utilizable salt thereof.

13. (Currently amended) The method of claim 12, wherein said voltage-gated sodium channel-inhibiting substance inhibitor is selected from the group consisting of tolperisone, eperisone, silperisone, riluzole, propafenone, lidocaine, flecainide, and metixen, or pharmaceutically utilizable salts thereof.

14. (Currently amended) The method of claim 12, wherein said voltage-gated sodium channel-inhibiting substance inhibitor is selected from the group consisting of tolperisone, eperisone, silperisone, and tolperisone analogs, and pharmaceutically utilizable salts thereof.

15. (Previously presented) A method of treating neuralgia pain or neuropathic pain, in a mammal, comprising administering to a patient in need thereof a therapeutically effective amount of a combination of retigabine with tolperisone, eperisone, silperisone, or tolperisone analog, or a pharmaceutically utilizable salt thereof.

16. (Withdrawn) The method of claim 12, wherein retigabine, or a pharmaceutically utilizable salt thereof, and said sodium channel-inhibiting or -influencing are administered separately or consecutively.

17. (Withdrawn) The method of claim 12, where said pains are associated with neuralgias.

18. (Withdrawn) The method of claim 12, where said pains are associated with arthritis and arthrosis.

19. (Withdrawn) The method of claim 12, where said pains are associated with chronic or episodic tension headache.

20. (Withdrawn) The method of claim 12, where said pains originate from a cause selected from lower spastic paraparesis syndrome, disturbances of the spinal blood circulation, and cerebral paralysis involving lower spastic paresis).

21. (Withdrawn) The method of claim 12, where said pains originate from a cause selected from lower paraspasm, transverse myelitis, multiple sclerosis, heritable inferior spastic paraplegia ("Stuempel paraplegia").

22. (Withdrawn) The method of claim 12, where said pains are associated with tetraparesis in connection with cervical myelopathy, cervical brachialgia or vertebral dysplasia.

23. (Canceled)

24. (Currently amended) The method of claim 12, wherein said voltage-gated sodium channel inhibiting substance inhibitor or therapeutically utilizable salt thereof is administered simultaneously with retigabine.

25. (Currently amended) The method of claim 12, wherein retigabine, or a therapeutically utilizable salt thereof, and said voltage-gated sodium channel inhibiting substance inhibitor are administered separately or consecutively.

26. (Previously presented) The method of claim 12, wherein said neuralgia pain or neuropathic pain is accompanied by an increase in muscle tone.

27. (Previously presented) The method of claim 15, wherein said neuralgia pain or neuropathic pain is accompanied by an increase in muscle tone.

28. (Previously presented) The method of any one of claims 12 or 15, wherein said mammal is a human.